Y Intercept Hong Kong Ltd Takes $939,000 Position in Haleon PLC Sponsored ADR $HLN

Y Intercept Hong Kong Ltd bought a new position in shares of Haleon PLC Sponsored ADR (NYSE:HLN) in the first quarter, Holdings Channel reports. The institutional investor bought 93,822 shares of the company’s stock, valued at approximately $939,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of HLN. Norges Bank purchased a new stake in Haleon during the 4th quarter worth approximately $163,529,000. Natixis Advisors LLC lifted its position in shares of Haleon by 429.8% in the fourth quarter. Natixis Advisors LLC now owns 10,003,941 shares of the company’s stock valued at $101,140,000 after acquiring an additional 8,115,633 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in shares of Haleon by 4,315.4% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 8,027,189 shares of the company’s stock worth $81,155,000 after acquiring an additional 7,845,391 shares during the last quarter. Bank of Montreal Can increased its position in shares of Haleon by 454.1% during the fourth quarter. Bank of Montreal Can now owns 8,500,496 shares of the company’s stock worth $85,940,000 after purchasing an additional 6,966,416 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in Haleon by 116.7% in the 2nd quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock valued at $128,423,000 after purchasing an additional 6,669,923 shares in the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Stock Performance

Shares of Haleon stock opened at $9.77 on Monday. Haleon PLC Sponsored ADR has a 52 week low of $8.65 and a 52 week high of $11.28. The business’s fifty day simple moving average is $9.20 and its 200-day simple moving average is $9.86. The firm has a market cap of $43.04 billion, a PE ratio of 25.04, a price-to-earnings-growth ratio of 2.26 and a beta of 0.13. The company has a quick ratio of 0.71, a current ratio of 0.92 and a debt-to-equity ratio of 0.47.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on HLN shares. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Haleon in a report on Thursday, April 30th. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a research report on Tuesday, June 30th. Rothschild & Co Redburn lowered shares of Haleon from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 16th. Argus upgraded shares of Haleon to a “strong-buy” rating in a report on Tuesday, March 17th. Finally, Wall Street Zen raised shares of Haleon from a “hold” rating to a “buy” rating in a research note on Sunday. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy”.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.